NeuroSense Therapeutics Ltd. SEC filings NRSNW
NeuroSense Therapeutics Ltd. has 314 filings in SEC EDGAR's recent list, going back to Aug 9, 2021. Its latest annual report, Form 20-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 2, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| F-3/A | Amendment no. 1 to form f-3 | Jul 30, 2026 | — |
| F-3 | Shelf registration (foreign issuer) | Jan 29, 2026 | — |
| 424B3 | Prospectus | Nov 26, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Oct 28, 2025 | — |
| S-8 | Employee stock plan registration | Aug 15, 2025 | — |
| POS AM | Post-effective amendment no. 2 to form f-1 | Aug 15, 2025 | — |
| POS AM | Post-effective amendment no. 4 to form f-1 | Aug 15, 2025 | — |
| 424B5 | Prospectus supplement | Aug 8, 2025 | — |
| POS AM | Post-effective amendment no 1 to form f-1 | Apr 11, 2025 | — |
| POS AM | Post-effective amendment no. 3 to form f-1 | Apr 11, 2025 | — |
| 424B5 | Prospectus supplement | Feb 21, 2025 | — |
| 424B3 | Prospectus | Jan 17, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Dec 26, 2024 | — |
| 424B3 | Prospectus | Dec 12, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | Dec 6, 2024 | — |
| 424B3 | Prospectus | Nov 22, 2024 | — |
| F-1 | Registration statement (foreign issuer) | Nov 19, 2024 | — |
| POS AM | Post-effective amendment | Oct 1, 2024 | — |
| 424B5 | Prospectus supplement | Aug 16, 2024 | — |
| 424B3 | Prospectus | Jun 27, 2024 | — |
| 424B3 | Prospectus | Jun 27, 2024 | — |
| 424B3 | Prospectus | Jun 17, 2024 | — |
| 424B3 | Prospectus | Jun 17, 2024 | — |
| 424B3 | Prospectus | May 22, 2024 | — |
| F-1/A | Amendment no. 1 to form f-1 | May 20, 2024 | — |
| F-1 | Registration statement (foreign issuer) | May 10, 2024 | — |
| 424B5 | Prospectus supplement | Apr 12, 2024 | — |
| POS AM | Post-effective amendment | Apr 4, 2024 | — |
| POS AM | Post-effective amendment no. 4 to form f-1 | Apr 4, 2024 | — |
| 424B3 | Prospectus | Dec 27, 2023 | — |
| 424B3 | Prospectus | Dec 14, 2023 | — |
| 424B3 | Prospectus | Dec 5, 2023 | — |
| 424B3 | Prospectus | Dec 5, 2023 | — |
| POS AM | Post-effective amendment no. 3 to form f-1 | Dec 4, 2023 | — |
| POS AM | Post-effective amendment no. 2 to form f-1 | Nov 21, 2023 | — |
| 424B3 | Prospectus | Sep 7, 2023 | — |
| F-1/A | Registration statement | Aug 31, 2023 | — |
| F-1/A | Registration statement | Aug 14, 2023 | — |
| F-1 | Registration statement (foreign issuer) | Jul 21, 2023 | — |
| 424B5 | Prospectus supplement | Jun 23, 2023 | — |
| 424B5 | Prospectus supplement | Jun 22, 2023 | — |
| 424B5 | Prospectus supplement | Apr 14, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | Jan 19, 2023 | — |
| 424B3 | Prospectus | Jul 28, 2022 | — |
| 424B3 | Prospectus | Apr 15, 2022 | — |
| POS AM | Post-effective amendment no. 1 to form f-1 | Apr 15, 2022 | — |
| S-8 | Employee stock plan registration | Feb 2, 2022 | — |
| 424B4 | Prospectus | Dec 10, 2021 | — |
| FWP | Free writing prospectus | Dec 6, 2021 | — |
| F-1/A | Registration statement | Dec 6, 2021 | — |
| F-1/A | Registration statement | Nov 19, 2021 | — |
| FWP | Free writing prospectus | Nov 10, 2021 | — |
| F-1/A | Registration statement | Nov 10, 2021 | — |
| F-1/A | Registration statement | Nov 1, 2021 | — |
| F-1 | Registration statement (foreign issuer) | Oct 18, 2021 | — |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRSN (Nasdaq), NRSNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Herzliya, Israel
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1875091
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.